Grzegorz Procyk
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Grzegorz Procyk has a total of 106 co-authors. Here are the top co-authors by number of shared publications:
- Aleksandra Gąsecka
1st Chair and Department of Cardiology, Medical University of Warsaw, Warsaw, Poland
13 shared publications - Marcin Grabowski
1st Department of Cardiology, Medical University of Warsaw, Stefana Banacha 1a, 02-097 Warsaw, Poland
5 shared publications Aleksandra Gąsecka
4 shared publications- Olga Grodzka
Department of Neurology, Faculty of Medicine and Dentistry, Medical University of Warsaw, Poland
4 shared publications - Małgorzata Wrzosek
Department of Pharmaceutical Sciences, Collegium Medicum, Jan Kochanowski University, IX Wieków Kielc 19a, 25-516 Kielce, Poland
3 shared publications - Adam Torbicki
Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education, European Health Centre Otwock, Otwock, Poland
2 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1941
Interleukin-6, soluble interleukin-6 receptor, and outcomes after transcatheter aortic valve implantation: an exploratory biomarker substudy of a prospective multicenter cohort
- 10 November 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1941
Open AccessInterleukin-6, soluble interleukin-6 receptor, and outcomes after transcatheter aortic valve implantation: an exploratory biomarker substudy of a prospective multicenter cohort
- Open Access
- 5 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8614
Reclassification of Clinical Familial Hypercholesterolemia Diagnoses After Adjustment of LDL-C for Lipoprotein(a) Cholesterol: A Systematic Review and Meta-Analysis
Background/Objectives: Low-density lipoprotein cholesterol (LDL-C) measurements include cholesterol carried by lipoprotein(a) [Lp(a)], which may influence the clinical classification of familial hypercholesterolemia (FH). We aimed to systematically review the available evidence and estimate the pooled proportion of individuals reclassified to a lower FH diagnostic category after correction of LDL-C for estimated Lp(a)-cholesterol. Methods: Embase, PubMed, and Scopus were searched from inception through 9 October 2026. We included observational studies with cross-sectional analyses of adults aged ≥18 years evaluated for suspected FH using the Dutch Lipid Clinic Network (DLCN) criteria before and after LDL-C correction for Lp(a)-cholesterol. Lp(a)-cholesterol was estimated as 30% of Lp(a) mass. The primary endpoint was reclassification to a lower DLCN diagnostic category among participants with possible, probable, or definite FH at baseline. Random-effects models were used to estimate pooled proportions. Risk of bias was assessed using the JBI critical appraisal tool for cross-sectional studies. Results: Four studies comprising 2970 individuals were included. The primary analysis included 2793 participants with possible, probable, or definite FH at baseline. After LDL-C correction for estimated Lp(a)-cholesterol, 19.8% (95% CI, 15.9–24.5) were reclassified to a lower DLCN diagnostic category. Conclusions: Correction of LDL-C for estimated Lp(a)-cholesterol resulted in downward DLCN reclassification in approximately one in five adults with at least possible FH from selected referral populations. The clinical utility of this adjustment, including its consequences for genetic testing and missed FH diagnoses, needs to be investigated.
- 5 November 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (21) , 8614
Open AccessReclassification of Clinical Familial Hypercholesterolemia Diagnoses After Adjustment of LDL-C for Lipoprotein(a) Cholesterol: A Systematic Review and Meta-Analysis
Background/Objectives: Low-density lipoprotein cholesterol (LDL-C) measurements include cholesterol carried by lipoprotein(a) [Lp(a)], which may influence the clinical classification of familial hypercholesterolemia (FH). We aimed to systematically review the available evidence and estimate the pooled proportion of individuals reclassified to a lower FH diagnostic category after correction of LDL-C for estimated Lp(a)-cholesterol. Methods: Embase, PubMed, and Scopus were searched from inception through 9 October 2026. We included observational studies with cross-sectional analyses of adults aged ≥18 years evaluated for suspected FH using the Dutch Lipid Clinic Network (DLCN) criteria before and after LDL-C correction for Lp(a)-cholesterol. Lp(a)-cholesterol was estimated as 30% of Lp(a) mass. The primary endpoint was reclassification to a lower DLCN diagnostic category among participants with possible, probable, or definite FH at baseline. Random-effects models were used to estimate pooled proportions. Risk of bias was assessed using the JBI critical appraisal tool for cross-sectional studies. Results: Four studies comprising 2970 individuals were included. The primary analysis included 2793 participants with possible, probable, or definite FH at baseline. After LDL-C correction for estimated Lp(a)-cholesterol, 19.8% (95% CI, 15.9–24.5) were reclassified to a lower DLCN diagnostic category. Conclusions: Correction of LDL-C for estimated Lp(a)-cholesterol resulted in downward DLCN reclassification in approximately one in five adults with at least possible FH from selected referral populations. The clinical utility of this adjustment, including its consequences for genetic testing and missed FH diagnoses, needs to be investigated.
- Open Access
- 27 October 2026
- Published by Elsevier in Advances in Medical Sciences
- Vol. 71 (2) , 413-421
Shock teams may improve outcomes of patients with cardiogenic shock (STOP-CS): a systematic review and meta-analysis
- 27 October 2026
- Published by Elsevier in Advances in Medical Sciences
- Vol. 71 (2) , 413-421
Open AccessShock teams may improve outcomes of patients with cardiogenic shock (STOP-CS): a systematic review and meta-analysis
- Open Access
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5133
COACH Study: COVID-19 Influence on Cardiorespiratory Fitness in Athletes—A Systematic Review and Meta-Analysis
Objectives: We aimed to systematically review and meta-analyze the impact of COVID-19 infection on cardiorespiratory fitness (CRF): (1) within-athlete (the same participants before and after infection), and (2) between-athlete (infected vs. healthy reference participants). Methods: In this systematic review (PROSPERO Registry: CRD42024540430) we included observational studies enrolling recreational or competitive athletes ≥18 years old with laboratory confirmation of SARS-CoV-2 infection. The primary outcome was change in relative maximal oxygen uptake (VO2max). Secondary outcomes included changes in absolute VO2max, maximal ventilation (VEmax), and maximal heart rate (HRmax). We searched Embase, PubMed, Medline, Scopus, and Web of Science up to August 9th, 2025. Risk of bias was assessed with the JBI critical appraisal tool. Meta-analyses were performed with a random-effects model. Results: Twelve studies enrolling a total of 1595 participants met the eligibility criteria. COVID-19 infection was associated with lower relative VO2max (MD = −1.83 mL·kg−1·min−1; 95%CI [−3.16, −0.49]; p = 0.007; I2 = 54%) and absolute VO2max (MD = −0.15 L·min−1; 95%CI [−0.29, −0.01]; p = 0.03; I2 = 0%). COVID-19 infection was associated with lower VEmax (MD = −7.99 L·min−1; 95%CI [−12.94, −3.04]; p = 0.002; I2 = 0%) but not with HRmax (MD = −0.34 bpm; 95%CI [−1.54, 0.86]; p = 0.58; I2 = 0%). High heterogeneity of included studies was addressed with subgroup analyses. The risk of bias in most studies was high. The certainty of evidence was very low for each outcome. Conclusions: COVID-19 infection in athletes was associated with reduced VO2max and VEmax. The relationships were highly dependent on the quality of the studies. CRF and athlete profile should be considered when making shared decisions regarding safe return to sport after infection.
- 1 July 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (13) , 5133
Open AccessCOACH Study: COVID-19 Influence on Cardiorespiratory Fitness in Athletes—A Systematic Review and Meta-Analysis
Objectives: We aimed to systematically review and meta-analyze the impact of COVID-19 infection on cardiorespiratory fitness (CRF): (1) within-athlete (the same participants before and after infection), and (2) between-athlete (infected vs. healthy reference participants). Methods: In this systematic review (PROSPERO Registry: CRD42024540430) we included observational studies enrolling recreational or competitive athletes ≥18 years old with laboratory confirmation of SARS-CoV-2 infection. The primary outcome was change in relative maximal oxygen uptake (VO2max). Secondary outcomes included changes in absolute VO2max, maximal ventilation (VEmax), and maximal heart rate (HRmax). We searched Embase, PubMed, Medline, Scopus, and Web of Science up to August 9th, 2025. Risk of bias was assessed with the JBI critical appraisal tool. Meta-analyses were performed with a random-effects model. Results: Twelve studies enrolling a total of 1595 participants met the eligibility criteria. COVID-19 infection was associated with lower relative VO2max (MD = −1.83 mL·kg−1·min−1; 95%CI [−3.16, −0.49]; p = 0.007; I2 = 54%) and absolute VO2max (MD = −0.15 L·min−1; 95%CI [−0.29, −0.01]; p = 0.03; I2 = 0%). COVID-19 infection was associated with lower VEmax (MD = −7.99 L·min−1; 95%CI [−12.94, −3.04]; p = 0.002; I2 = 0%) but not with HRmax (MD = −0.34 bpm; 95%CI [−1.54, 0.86]; p = 0.58; I2 = 0%). High heterogeneity of included studies was addressed with subgroup analyses. The risk of bias in most studies was high. The certainty of evidence was very low for each outcome. Conclusions: COVID-19 infection in athletes was associated with reduced VO2max and VEmax. The relationships were highly dependent on the quality of the studies. CRF and athlete profile should be considered when making shared decisions regarding safe return to sport after infection.
- Open Access
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
The role of non-coding RNAs in the coronary no-reflow phenomenon: a systematic review
Coronary no-reflow poses a challenge in interventional cardiology. Increasing attention has been directed toward the potential role of non-coding RNAs (ncRNAs) in predicting coronary no-reflow (CNR), with no prior systematic review available to date. We aimed to systematically review the available evidence on the potential clinical utility of ncRNAs in CNR and/or microvascular obstruction (MVO). Embase, MEDLINE Ultimate, PubMed, Scopus, and Web of Science were searched, last on February 9, 2026. Studies enrolling adult patients with CNR and/or MVO that evaluated the expression of ncRNAs or investigated genetic variants within ncRNA-related pathways were included. Risk of bias was not assessed. Upregulation of miR-1, miR-7a/b, miR-98-5p, miR-133a, miR-133b, miR-208a, miR-224-3p, miR-660-5p, long non-coding RNA (lncRNA) TUG1, lncRNA MALAT1, and downregulation of miR-30e, miR-126, miR-155, and miR-542-3p were reported in patients with STEMI with CNR and/or MVO compared with those without CNR/MVO. Almost all ncRNAs were reported by a single study, with the exception of miR-30e, which was consistently reported in three independent studies. Several ncRNAs may demonstrate good performance in identifying patients at risk of CNR and/or MVO occurrence. Nevertheless, the available evidence is scarce and limited by the low robustness of the reported findings. Circulating ncRNAs are promising biomarkers for CNR. Nevertheless, several limitations persist, highlighting the need for further studies with standardized methodology to validate the clinical utility of ncRNAs.
- 27 May 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1)
Open AccessThe role of non-coding RNAs in the coronary no-reflow phenomenon: a systematic review
Coronary no-reflow poses a challenge in interventional cardiology. Increasing attention has been directed toward the potential role of non-coding RNAs (ncRNAs) in predicting coronary no-reflow (CNR), with no prior systematic review available to date. We aimed to systematically review the available evidence on the potential clinical utility of ncRNAs in CNR and/or microvascular obstruction (MVO). Embase, MEDLINE Ultimate, PubMed, Scopus, and Web of Science were searched, last on February 9, 2026. Studies enrolling adult patients with CNR and/or MVO that evaluated the expression of ncRNAs or investigated genetic variants within ncRNA-related pathways were included. Risk of bias was not assessed. Upregulation of miR-1, miR-7a/b, miR-98-5p, miR-133a, miR-133b, miR-208a, miR-224-3p, miR-660-5p, long non-coding RNA (lncRNA) TUG1, lncRNA MALAT1, and downregulation of miR-30e, miR-126, miR-155, and miR-542-3p were reported in patients with STEMI with CNR and/or MVO compared with those without CNR/MVO. Almost all ncRNAs were reported by a single study, with the exception of miR-30e, which was consistently reported in three independent studies. Several ncRNAs may demonstrate good performance in identifying patients at risk of CNR and/or MVO occurrence. Nevertheless, the available evidence is scarce and limited by the low robustness of the reported findings. Circulating ncRNAs are promising biomarkers for CNR. Nevertheless, several limitations persist, highlighting the need for further studies with standardized methodology to validate the clinical utility of ncRNAs.
- 18 February 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (3) , 137
The role of microRNAs in Kawasaki disease: a systematic review
Kawasaki disease (KD) is an acute vasculitis affecting medium-sized vessels and characterized by fever lasting more than 5 days. Differential diagnosis of KD is challenging. Microribonucleic acids (miRNA/miR) have been widely studied as potential biomarkers for diagnosing KD. The objective of this study is to systematically review the clinical utility of miRNAs in KD. This systematic review followed the PRISMA 2020 guidelines. We included English-language, full-text observational studies enrolling adult and/or pediatric patients with KD (complete or incomplete) which quantified miRNA expression levels or genotyped single-nucleotide polymorphisms (SNPs) in miRNA genes. We searched the following databases: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science. Each database was last searched on January 12, 2026. Thirty-six studies met the eligibility criteria and were included in this review. The most reproducible finding concerns miR-223 which has been repeatedly reported to be upregulated in KD patients compared with both healthy and febrile controls. Several miRNAs have been described to distinguish specific KD phenotypes, e.g., coronary artery lesion (CAL) formation and intravenous immunoglobulin (IVIG) responsiveness. The majority of investigated SNPs in miRNA genes were not associated with KD susceptibility; however, some associations were reported, including with KD phenotypes such as CAL formation. Conclusions: Multiple studies have shown dysregulation of miRNA expression in KD patients and the potential utility of miRNAs in diagnosing KD and identifying individuals at risk of CAL formation or IVIG resistance. Nevertheless, there is a need for methodological standardization in future research and for studies including multiethnic cohorts. What’s Known? • No single test for Kawasaki Disease is available; it can be diagnosed in patients meeting the clinical criteria. • Microribonucleic acids are promising biomarkers in various cardiovascular conditions including Kawasaki Disease. What’s New? • To the best of our knowledge, this is the first systematic review evaluating microribonucleic acids in Kawasaki Disease using PRISMA guidelines. • Studies regarding the role of microribonucleic acids in Kawasaki Disease are highly heterogeneous but several of them display significant potential as diagnostic biomarkers. Graphical Abstract
- 18 February 2026
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 185 (3) , 137
The role of microRNAs in Kawasaki disease: a systematic review
Kawasaki disease (KD) is an acute vasculitis affecting medium-sized vessels and characterized by fever lasting more than 5 days. Differential diagnosis of KD is challenging. Microribonucleic acids (miRNA/miR) have been widely studied as potential biomarkers for diagnosing KD. The objective of this study is to systematically review the clinical utility of miRNAs in KD. This systematic review followed the PRISMA 2020 guidelines. We included English-language, full-text observational studies enrolling adult and/or pediatric patients with KD (complete or incomplete) which quantified miRNA expression levels or genotyped single-nucleotide polymorphisms (SNPs) in miRNA genes. We searched the following databases: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science. Each database was last searched on January 12, 2026. Thirty-six studies met the eligibility criteria and were included in this review. The most reproducible finding concerns miR-223 which has been repeatedly reported to be upregulated in KD patients compared with both healthy and febrile controls. Several miRNAs have been described to distinguish specific KD phenotypes, e.g., coronary artery lesion (CAL) formation and intravenous immunoglobulin (IVIG) responsiveness. The majority of investigated SNPs in miRNA genes were not associated with KD susceptibility; however, some associations were reported, including with KD phenotypes such as CAL formation. Conclusions: Multiple studies have shown dysregulation of miRNA expression in KD patients and the potential utility of miRNAs in diagnosing KD and identifying individuals at risk of CAL formation or IVIG resistance. Nevertheless, there is a need for methodological standardization in future research and for studies including multiethnic cohorts. What’s Known? • No single test for Kawasaki Disease is available; it can be diagnosed in patients meeting the clinical criteria. • Microribonucleic acids are promising biomarkers in various cardiovascular conditions including Kawasaki Disease. What’s New? • To the best of our knowledge, this is the first systematic review evaluating microribonucleic acids in Kawasaki Disease using PRISMA guidelines. • Studies regarding the role of microribonucleic acids in Kawasaki Disease are highly heterogeneous but several of them display significant potential as diagnostic biomarkers. Graphical Abstract
- 12 January 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (1) , 137
PRODIGY Reclassification May Alter the Meta-Analytical Results on Aspirin vs P2Y12 Inhibitor Monotherapy After Short DAPT
- 12 January 2026
- Published by Elsevier in JACC: Cardiovascular Interventions
- Vol. 19 (1) , 137
PRODIGY Reclassification May Alter the Meta-Analytical Results on Aspirin vs P2Y12 Inhibitor Monotherapy After Short DAPT
- Open Access
- 20 October 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2246-2257
Incorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.
- 20 October 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
- Vol. 21 (6) , 2246-2257
Open AccessIncorporating lipoprotein (a) into patient care: Polish landscape in light of national recommendations and the updated ESC/EAS guidelines
Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of death in Poland. Lipoprotein (a) [Lp(a)] constitutes an independent, causal risk factor for ASCVD and aortic valve stenosis. Elevated Lp(a) is found in approximately 20% of the Polish population. Lp(a) measurements have been recommended in all adult patients to improve cardiovascular risk stratification. As the testing rate remains insufficient, there is a need to facilitate the incorporation of Lp(a) into routine patient care. This clinically oriented review outlines (i) up-to-date evidence on the role of Lp(a) in cardiovascular diseases, (ii) recent real-world data on the characteristics of Polish patients with elevated Lp(a), and (iii) strategies for Lp(a) testing and management in light of the current national recommendations and the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidemias.
- 11 September 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (2) , 346-352
Sex-based differences in patients with acute pulmonary embolism managed by a pulmonary embolism response team: a multicenter, retrospective cohort study
- 11 September 2025
- Published by Elsevier in Advances in Medical Sciences
- Vol. 70 (2) , 346-352
Sex-based differences in patients with acute pulmonary embolism managed by a pulmonary embolism response team: a multicenter, retrospective cohort study
- Open Access
- 26 May 2025
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 90, 224-233
Imaging modalities used in follow-up after coil embolization of splenic artery aneurysm – a systematic review
Purpose: Endovascular procedures have become the method of choice for treating splenic artery aneurysms (SSAs). However, there is no consensus regarding the intervals and imaging methods for follow-up examinations in patients with true SAAs treated with coil embolisation. We aimed to evaluate the utility of digital subtraction angiography (DSA), computed tomography angiography (CTA), magnetic resonance angiography (MRA), contrast-enhanced ultrasound, and duplex ultrasound (DUS) for follow-up screening of patients with SAAs treated with coil embolisation.Material and methods: We conducted a systematic review according to the PRISMA 2020 Statement. We searched 5 databases: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science, each up to 10 April 2024. Eventually, 20 relevant original studies were included.Results: DSA is an invasive procedure that requires ionising radiation and should not be performed as a routine check-up. CTA is an appropriate examination method in patients immediately after coil embolisation in whom severe complications, primarily bleeding, are suspected. Still, it is unsuitable for assessing persistent aneurysmal sac perfusion. MRA is a promising noninvasive technique that does not require ionising radiation. Several studies have demonstrated the superiority of MRA over DSA in detecting small aneurysmal sac reperfusion. DUS, while not a standalone method, may supplement MRA in patients at low risk of reintervention.Conclusions: The evidence regarding follow-up imaging methods after SAAs coil embolisation is limited and of low quality. MRA should be preferred over DSA for detecting aneurysmal sac reperfusion. Due to artifacts, CTA is suitable for emergency cases but not for routine follow-up.
- 26 May 2025
- Published by Termedia Sp. z.o.o. in Polish Journal of Radiology
- Vol. 90, 224-233
Open AccessImaging modalities used in follow-up after coil embolization of splenic artery aneurysm – a systematic review
Purpose: Endovascular procedures have become the method of choice for treating splenic artery aneurysms (SSAs). However, there is no consensus regarding the intervals and imaging methods for follow-up examinations in patients with true SAAs treated with coil embolisation. We aimed to evaluate the utility of digital subtraction angiography (DSA), computed tomography angiography (CTA), magnetic resonance angiography (MRA), contrast-enhanced ultrasound, and duplex ultrasound (DUS) for follow-up screening of patients with SAAs treated with coil embolisation.Material and methods: We conducted a systematic review according to the PRISMA 2020 Statement. We searched 5 databases: Embase, Medline Ultimate, PubMed, Scopus, and Web of Science, each up to 10 April 2024. Eventually, 20 relevant original studies were included.Results: DSA is an invasive procedure that requires ionising radiation and should not be performed as a routine check-up. CTA is an appropriate examination method in patients immediately after coil embolisation in whom severe complications, primarily bleeding, are suspected. Still, it is unsuitable for assessing persistent aneurysmal sac perfusion. MRA is a promising noninvasive technique that does not require ionising radiation. Several studies have demonstrated the superiority of MRA over DSA in detecting small aneurysmal sac reperfusion. DUS, while not a standalone method, may supplement MRA in patients at low risk of reintervention.Conclusions: The evidence regarding follow-up imaging methods after SAAs coil embolisation is limited and of low quality. MRA should be preferred over DSA for detecting aneurysmal sac reperfusion. Due to artifacts, CTA is suitable for emergency cases but not for routine follow-up.